Xiao Ding1, Qianqian Li1, Pan Li2, Xiong Chen3, Liyuan Xiang1, Liangwen Bi4, Jianguo Zhu5, Xiujiang Huang6, Bota Cui2, Faming Zhang7. 1. Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, China. 2. Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, China; Key Lab of Holistic Integrative Enterology, Nanjing Medical University, China. 3. Department of Medical Oncology, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzhou, China. 4. Department of Radiotherapy, the Second Affiliated Hospital of Nanjing Medical University, China. 5. Department of Radiology, the Second Affiliated Hospital of Nanjing Medical University, China. 6. Department of Gastroenterology, People's Hospital of Qiandongnan Prefecture, China. 7. Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, China; Key Lab of Holistic Integrative Enterology, Nanjing Medical University, China. Electronic address: fzhang@njmu.edu.cn.
Abstract
BACKGROUND: Increasing evidence has indicated that gut microbiota is closely associated with radiation-induced bowel injury. We aimed to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in patients with chronic radiation enteritis (CRE). METHODS: A pilot study of FMT for CRE was performed. The primary outcomes were safety and response to FMT which was defined as a ≥1-grade reduction in Radiation Therapy Oncology Group (RTOG/EORTC) late toxicity grade from baseline, by 8 weeks post-FMT. The secondary outcomes included a decrease in the severity of four common symptoms (diarrhea, rectal hemorrhage, abdominal/rectal pain and fecal incontinence) in CRE and changes in Karnofsky Performance Status (KPS) score. Microbial analyses were performed by 16S rRNA sequencing. RESULTS: Five female patients underwent FMT from January to November 2018 with a median age of 58 (range 45-81) years. The median baseline RTOG/EORTC grade was 2 (range 2-4). Three patients responded to FMT and experienced improvement in diarrhea, rectal hemorrhage, abdominal/rectal pain and fecal incontinence as well as a decrease in KPS score. No FMT-related death and infectious complications occurred. One mild FMT-related AE was observed during a follow-up ranged from 8 to 18 months. 16S rRNA sequencing indicated that FMT altered the composition of gut microbiota of patients. CONCLUSION: The present case series first demonstrated that FMT might be safe and effective to improve intestinal symptoms and mucosal injury in patients with CRE for a period of time. Trial registration ID: NCT03516461.
BACKGROUND: Increasing evidence has indicated that gut microbiota is closely associated with radiation-induced bowel injury. We aimed to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in patients with chronic radiation enteritis (CRE). METHODS: A pilot study of FMT for CRE was performed. The primary outcomes were safety and response to FMT which was defined as a ≥1-grade reduction in Radiation Therapy Oncology Group (RTOG/EORTC) late toxicity grade from baseline, by 8 weeks post-FMT. The secondary outcomes included a decrease in the severity of four common symptoms (diarrhea, rectal hemorrhage, abdominal/rectal pain and fecal incontinence) in CRE and changes in Karnofsky Performance Status (KPS) score. Microbial analyses were performed by 16S rRNA sequencing. RESULTS: Five female patients underwent FMT from January to November 2018 with a median age of 58 (range 45-81) years. The median baseline RTOG/EORTC grade was 2 (range 2-4). Three patients responded to FMT and experienced improvement in diarrhea, rectal hemorrhage, abdominal/rectal pain and fecal incontinence as well as a decrease in KPS score. No FMT-related death and infectious complications occurred. One mild FMT-related AE was observed during a follow-up ranged from 8 to 18 months. 16S rRNA sequencing indicated that FMT altered the composition of gut microbiota of patients. CONCLUSION: The present case series first demonstrated that FMT might be safe and effective to improve intestinal symptoms and mucosal injury in patients with CRE for a period of time. Trial registration ID: NCT03516461.
Authors: Selina E Eaton; Justyna Kaczmarek; Daanish Mahmood; Anna M McDiarmid; Alya N Norarfan; Erin G Scott; Chee Kin Then; Hailey Y Tsui; Anne E Kiltie Journal: Br J Cancer Date: 2022-09-29 Impact factor: 9.075
Authors: Brynn A Hollingsworth; David R Cassatt; Andrea L DiCarlo; Carmen I Rios; Merriline M Satyamitra; Thomas A Winters; Lanyn P Taliaferro Journal: Front Pharmacol Date: 2021-05-18 Impact factor: 5.810
Authors: Byeongsang Oh; Thomas Eade; Gillian Lamoury; Susan Carroll; Marita Morgia; Andrew Kneebone; George Hruby; Mark Stevens; Frances Boyle; Stephen Clarke; Brian Corless; Mark Molloy; David Rosenthal; Michael Back Journal: Cancers (Basel) Date: 2021-05-13 Impact factor: 6.639